Lauren A. Baldassarre, MD, FACC
Cards
About
Research
Publications
2024
GEDATOLISIB ASSOCIATED ACUTE MYOCARDITIS IN A PATIENT WITH BREAST CANCER
Shen M, Khattab M, Akintoye E, Baldassarre L, Kwan J. GEDATOLISIB ASSOCIATED ACUTE MYOCARDITIS IN A PATIENT WITH BREAST CANCER. Journal Of The American College Of Cardiology 2024, 83: 3575. DOI: 10.1016/s0735-1097(24)05565-7.Peer-Reviewed Original ResearchMultimodality Cardiac Imaging and the Imaging Workforce in the United States: Diversity, Disparities, and Future Directions
Bullock-Palmer R, Rosario K, Douglas P, Hahn R, Lang R, Chareonthaitawee P, Srichai M, Ordovas K, Baldassarre L, Burroughs M, Henderson C, Woodard P, Pressoir K, Swaminathan M, Blankstein R, Daubert M. Multimodality Cardiac Imaging and the Imaging Workforce in the United States: Diversity, Disparities, and Future Directions. Circulation Cardiovascular Imaging 2024, 17: e016409. PMID: 38377238, DOI: 10.1161/circimaging.123.016409.Peer-Reviewed Original Research
2023
Multimodality Evaluation of Spontaneous Coronary Artery Dissection in a Patient With Connective Tissue Disease: A Case Report
Shah T, Shah N, Baldassarre L, Freed L, Mojibian H, Shah S. Multimodality Evaluation of Spontaneous Coronary Artery Dissection in a Patient With Connective Tissue Disease: A Case Report. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101125. DOI: 10.1016/j.jscai.2023.101125.Peer-Reviewed Case Reports and Technical NotesSGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injuryAtrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation
Lamy J, Taoutel R, Chamoun R, Akar J, Niederer S, Mojibian H, Huber S, Baldassarre L, Meadows J, Peters D. Atrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation. The International Journal Of Cardiovascular Imaging 2023, 40: 107-117. PMID: 37857929, DOI: 10.1007/s10554-023-02968-x.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementLA reservoir strainLeft atrial pressureLA volumeReservoir strainLA fibrosisLA strainStiffness indexLA late gadolinium enhancementAtrial stiffness indexMaximal LA volumeAtrial fibrillation cohortLA minimum volumeAtrial tissue fibrosisMaximum LA volumeCardiac MR examsAtrial stiffnessAtrial strainAF ablationAtrial pressureAF cohortAtrial fibrillationAtrial fibrosisPatient subgroupsLGE volumeScientific document development standards for the society of cardiovascular computed tomography (SCCT): A statement from the SCCT Guidelines Committee
Baldassarre L, Koweek L, Andreini D, Branch K, Brennaman D, Budde R, De La O S, Fairbairn T, Hedgire S, Weir-McCall J, Woodard P, Wong D, Chen M, Committee S. Scientific document development standards for the society of cardiovascular computed tomography (SCCT): A statement from the SCCT Guidelines Committee. Journal Of Cardiovascular Computed Tomography 2023, 17: 459-464. PMID: 37429770, DOI: 10.1016/j.jcct.2023.06.006.Peer-Reviewed Original ResearchQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin useAdvances in Coronary Computed Tomographic Angiographic Imaging of Atherosclerosis for Risk Stratification and Preventive Care
Bienstock S, Lin F, Blankstein R, Leipsic J, Cardoso R, Ahmadi A, Gelijns A, Patel K, Baldassarre L, Hadley M, LaRocca G, Sanz J, Narula J, Chandrashekhar Y, Shaw L, Fuster V. Advances in Coronary Computed Tomographic Angiographic Imaging of Atherosclerosis for Risk Stratification and Preventive Care. JACC Cardiovascular Imaging 2023, 16: 1099-1115. PMID: 37178070, DOI: 10.1016/j.jcmg.2023.02.002.Peer-Reviewed Original ResearchConceptsCoronary Computed Tomography AngiographyCoronary artery diseaseAtherosclerotic plaquesArtery diseaseRisk stratificationPreventive carePlaque volumeHigh-risk plaque featuresNonobstructive coronary artery diseaseCoronary CTAMeasurements of atherosclerosisEffective risk stratificationHigh-risk patientsTotal plaque volumeComputed tomography angiographyPatient-specific factorsCoronary artery dimensionsIntravascular ultrasound measurementsHealth care systemCoronary dominanceCardiovascular preventionPatient subsetsPlaque featuresArtery sizeTomography angiographyImpaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis
Feher A, Miller E, Peters D, Mojibian H, Sinusas A, Hinchcliff M, Baldassarre L. Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis. Rheumatology International 2023, 43: 849-858. PMID: 36894756, DOI: 10.1007/s00296-023-05294-6.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementLV-GLSSystemic sclerosisWorse survivalClinical indicationsImpaired left ventricular global longitudinal strainLeft ventricular global longitudinal strainPresence of LGECMR strainLV cardiac indexWorse LV-GLSLV ejection fractionCox regression analysisGlobal longitudinal strainLV cardiac outputGlobal radialCardiac indexOverall survivalRetrospective cohortEjection fractionPrognostic valueAdverse outcomesCardiac outputGadolinium enhancementRV strainRacial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.
Zhu C, Shi T, Jiang C, Liu B, Baldassarre L, Zarich S. Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S. JACC CardioOncology 2023, 5: 55-66. PMID: 36875907, PMCID: PMC9982284, DOI: 10.1016/j.jaccao.2022.10.013.Peer-Reviewed Original ResearchCVD mortalityYears of ageCancer patientsEthnic disparitiesHigh-risk cancer populationLong-term survivorship careNon-Hispanic Black individualsNH-White patientsEnd Results (SEER) databaseCardiovascular disease mortalityNH Asian/Pacific IslanderMost prevalent cancersAsian/Pacific IslandersAdjusted HRsPatients 18Cardiovascular mortalityClinical characteristicsLocalized cancerSurvivorship careWhite patientsResults databaseCancer populationCancer survivalDisease mortalityMalignancy diagnosis
Clinical Trials
Current Trials
Advanced Cardiovascular Magnetic Resonance for Detection of Programmed Cell Death Protein-1 Deficient Myocarditis
HIC ID2000023943RolePrincipal InvestigatorPrimary Completion Date10/29/2024Recruiting Participants
Academic Achievements and Community Involvement
Clinical Care
Overview
Lauren Baldassarre, MD, is a cardiologist at Yale Medicine and director of the Cardio-Oncology Program at the Yale Cancer Center.
Cardio-oncology is a relatively new field that helps patients manage the cardiac side effects of therapies they’re receiving for cancer treatment (such as chemotherapy, radiation and immunotherapy). The goal of the cardio-oncology program is to diagnose and treat those side effects as early as possible.
Dr. Baldassarre first became interested in cardio-oncology during her cardiology fellowship, and she decided to pursue and complete an additional year of fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. That fellowship focused on advanced cardiac imaging with cardiac MRI and caring for cancer patients with cardiac questions or complications. It was a way for Dr. Baldassarre to combine her interests in women’s heart disease and cardiac imaging, and introduced her to the field of cardio-oncology. In 2013, she arrived at Yale Medicine and became the director of the cardio-oncology program in 2015.
As the director, Dr. Baldassarre’s goals have been to offer care to any patient who might benefit from cardiovascular risk assessment and monitoring not only at the main hospital, but also at Yale Medicine satellite sites, and to expand research and clinical trials that investigate ways to diagnose cardiac complications from cancer earlier.
When meeting with new patients, Dr. Baldassarre takes a thorough history and physical and completes a cardiovascular risk assessment based on the type of cancer therapy they will be receiving. Patients can also expect to undergo some cardiac imaging as part of that risk assessment.
“I really hope to be able to put patients at ease,” says Dr. Baldassarre. “I know that patients are concerned especially when they’re going through so much already.” She walks them through established monitoring and treatments protocols, which may be used to prevent complications or treat them, if they do arise.
In addition to seeing patients, Dr. Baldassarre researches the cardiac side effects of immunotherapy, one of the most promising therapies for cancer. She is also an associate professor (cardiology) at Yale Medicine.
Clinical Specialties
Fact Sheets
CT Scan for Coronary Artery Disease
Learn More on Yale MedicineCoronary Artery Disease (CAD)
Learn More on Yale MedicineChronic Total Occlusion (CTO)
Learn More on Yale MedicineHeart Disease in Women
Learn More on Yale Medicine
Board Certifications
Cardiovascular Computed Tomography
- Certification Organization
- AB of Nuclear Cardiology
- Original Certification Date
- 2016
Cardiovascular Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2012
Cardiovascular Computed Tomography
- Certification Organization
- Certification Board of Cardiovascular Computed Tomography
- Original Certification Date
- 2012
Yale Medicine News
Links & Media
News
- July 24, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (July 2024)
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- June 09, 2023
Five faculty members receive Innovative Project Award for sarcoidosis research
- June 05, 2023
Discoveries & Impact (June 2023)
Get In Touch
Contacts
Cardiovascular Medicine
15 York Street, PO Box 208017
New Haven, CT 06520-8017
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.